You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on minimal residual disease testing.
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
Inivata's Radar assay will be used to monitor circulating tumor DNA from multiple tumor types in trial participants following treatment with Maverick's MVC-101 candidate.
The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.
The draft LCD would cover the Signatera minimal residual disease test for several solid tumor types and indications, including immunotherapy response monitoring.
The Signatera test is optimized for molecular residual disease (MRD) assessment and for monitoring treatment in cancer patients.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases.
ArcherDX said the firms aim to apply minimal residual disease monitoring in clinical-trial protocols and for future therapy optimization.
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).